TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) Operating cash flow 2016–2025
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$99.8MFY2025 · since FY2016: -$37.3M → -$99.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$99.8M | -63.9% |
| FY2024 | -$60.9M | +40.3% |
| FY2023 | -$102.0M | -4.0% |
| FY2022 | -$98.1M | -29.8% |
| FY2021 | -$75.6M | -55.6% |
| FY2020 | -$48.6M | -82.0% |
| FY2019 | -$26.7M | -11.3% |
| FY2018 | -$24.0M | -25.3% |
| FY2017 | -$19.1M | +48.7% |
| FY2016 | -$37.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TNXP financial trends
TNXP RevenueTNXP Net incomeTNXP Net marginTNXP Gross profitTNXP Gross marginTNXP Operating incomeTNXP Operating marginTNXP Free cash flowTNXP Capital expendituresTNXP Return on equityTNXP Stock buybacksTNXP Dividends paidTNXP Total assetsTNXP Total liabilitiesTNXP Shareholders’ equityTNXP overview →